$ALDX Lawsuit: Aldeyra Therapeutics, Inc. Sued for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses

Core Viewpoint - A securities fraud lawsuit has been filed against Aldeyra Therapeutics, Inc. following a significant drop in its stock price due to negative FDA feedback on its drug reproxalap for dry eye disease [1][2]. Group 1: Company Performance - Aldeyra Therapeutics' shares fell over 65% on March 17, 2026, after the company disclosed that the FDA issued a Complete Response Letter indicating that the application for reproxalap "failed to demonstrate efficacy in adequate and well controlled studies" [2]. - The FDA previously indicated that Aldeyra's New Drug Application (NDA) for reproxalap did not demonstrate efficacy in treating ocular symptoms associated with dry eyes and required at least one additional study to support its effectiveness [2]. Group 2: Investor Eligibility - Investors who purchased Aldeyra Therapeutics common stock between November 3, 2023, and March 16, 2026, and experienced a decline in their investment may be eligible to participate in the lawsuit, regardless of whether they sold their shares [3]. Group 3: Legal Process - The deadline for investors to seek appointment as lead plaintiff in the lawsuit is May 29, 2026, and a class has not yet been certified [4]. - Investors who have lost money are encouraged to contact Block & Leviton for more information on their rights and options [4]. Group 4: Whistleblower Information - Individuals with non-public information about Aldeyra Therapeutics are encouraged to assist in the investigation or file a report with the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [5]. Group 5: Legal Representation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [6].